参考文献/References:
[1] Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding[J]. Lancet, 2020, 395(1224): 565-574.
[2] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(1223): 497-506.
[3] Zhu N, Zhang DY, Wang WL, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8): 727-733.
[4] Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020, 382(18): 1708-1720.
[5] Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in wuhan, China[J]. JAMA Cardiol, 2020, 5(7): 802-810.
[6] Fei Z, Yu T, Du RH, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study[J]. Lancet, 2020, 395(1229): 1054-1062.
[7] Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China[J]. JAMA Intern Med, 2020, 180(7): 934-943.
[8] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579(7798): 270-273.
[9] Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in wuhan, China[J]. JAMA Neurol, 2020, 77(6): 683-690.
[10] Franceschi AM, Ahmed O, Giliberto L, et al. Hemorrhagic posterior reversible encephalopathy syndrome as a manifestation of COVID-19 infection[J]. AJNR Am J Neuroradiol, 2020, 41(7): 1173-1176.
[11] Poyiadji N, Shahin G, Noujaim D, et al. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features[J]. Radiology, 2020, 296(2): E119-E120.
[12] Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings[J]. Brain, 2020, 143(10): 3104-3120.
[13] Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2[J]. Int J Infect Dis, 2020, 94(5): 55-58.
[14] Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré syndrome associated with SARS-CoV-2[J]. N Engl J Med, 2020, 382(26): 2574-2576.
[15] Oxley TJ, Mocco J, Majidi S, et al. Large-Vessel stroke as a presenting feature of covid-19 in the young[J]. N Engl J Med, 2020, 382(20): e60.
[16] Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and renal tropism of SARS-CoV-2[J]. N Engl J Med, 2020, 383(6): 590-592.
[17] Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS[J]. J Exp Med, 2005, 202(3): 415-424.
[18] Li MY, Lin L, Yue Z, et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues[J]. Infect Dis Poverty, 2020, 9(1): 45.
[19] Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection[J]. N Engl J Med, 2020, 382(23): 2268-2270.
[20] Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19[J]. N Engl J Med, 2020, 383(2): 120-128.
[21] Xu H, Zhong L, Deng JX, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa[J]. Int J Oral Sci, 2020, 12(1): 8.
[22] Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and Consequences of cytokine storm and immunopathology[J]. Semin Immunopathol, 2017, 39(5): 529-539.
[23] Hotchkiss RS, Opal SM. Activating immunity to fight a foe - A new path[J]. N Engl J Med, 2020, 382(13): 1270-1272.
[24] Chu H, Zhou J, Wong BH, et al. Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways[J]. J Infect Dis, 2016, 213(6): 904-914.
[25] Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells[J]. Blood, 2007, 109(9): 3812-3819.
[26] Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China[J]. Intensive Care Med, 2020, 46(5): 846-848.
[27] Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 People with coronavirus disease 2019 in New York City: prospective cohort study[J]. BMJ, 2020, 369(5): m1966.
[28] Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study[J]. medRxiv, 2020, 395(10239): 2020.04.15.20067157.
[29] Price CC, Altice FL, Shyr Y, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: survival and clinical outcomes[J]. Chest, 2020, 158(4): 1397-1408.
[30] Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19[J]. Lancet, 2020, 395(1234): 1417-1418.
[31] Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity[J]. Nat Rev Immunol, 2013, 13(1): 34-45.
[32] Levi M, van der Poll T. Coagulation and sepsis[J]. Thromb Res, 2017, 149: 38-44.
[33] Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms[J]. Blood, 2019, 133(9): 906-918.
[34] Bikdeli B, Madhavan MV, Gupta A, et al. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research[J]. Thromb Haemost, 2020, 120(7): 1004-1024.
[35] Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia[J]. Thromb Res, 2019, 181(9): 77-83.
[36] Deshpande C. Thromboembolic findings in COVID-19 autopsies: pulmonary thrombosis or embolism?[J]. Ann Intern Med, 2020, 173(5): 394-395.